Avanza Fonder AB Buys 3,117 Shares of Stryker Corporation $SYK

Avanza Fonder AB increased its stake in shares of Stryker Corporation (NYSE:SYK) by 8.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 42,319 shares of the medical technology company’s stock after buying an additional 3,117 shares during the quarter. Avanza Fonder AB’s holdings in Stryker were worth $14,874,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Brighton Jones LLC raised its holdings in shares of Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after purchasing an additional 609 shares during the last quarter. Schnieders Capital Management LLC. purchased a new position in Stryker during the second quarter worth about $205,000. AlphaCore Capital LLC grew its position in Stryker by 81.3% in the 2nd quarter. AlphaCore Capital LLC now owns 1,048 shares of the medical technology company’s stock worth $414,000 after purchasing an additional 470 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Stryker by 1.0% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 2,035,557 shares of the medical technology company’s stock worth $805,327,000 after purchasing an additional 20,183 shares in the last quarter. Finally, Coldstream Capital Management Inc. increased its stake in Stryker by 16.2% in the 2nd quarter. Coldstream Capital Management Inc. now owns 9,759 shares of the medical technology company’s stock valued at $3,862,000 after buying an additional 1,363 shares during the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker reports containment of the cybersecurity incident and progress in system restoration; operations are stabilizing, which reduces near-term disruption risk. Stryker reports progress in restoration efforts after cyberattack, operations continue to stabilize
• Positive Sentiment: Market reaction showed short-term relief: several outlets noted shares briefly rose after the company said the incident was contained, reflecting lowered immediate operational risk. Stryker shares climb after company says cybersecurity incident contained
• Neutral Sentiment: Stryker announced its 2026 Annual Meeting of Shareholders — routine corporate governance item with limited direct market impact. Stryker announces Annual Meeting of Shareholders
• Neutral Sentiment: Analyst / sector comparisons (Envista, Intuitive Surgical) discuss valuation and growth positioning versus Stryker; useful for longer-term allocation decisions but not the day’s price driver. NVST or SYK: Which Is the Better Value Stock Right Now? Intuitive Surgical vs. Stryker: Which Surgical Tech Stock Leads?
• Negative Sentiment: Coverage emphasizes that attackers (including state-linked criminal groups) are mounting disruptive, multifaceted campaigns that can extract leverage beyond data theft — raising the risk of longer recovery costs, regulatory scrutiny, and reputation/competitive impacts. Stryker Cyberattack Highlights Criminal Focus on Enterprise Systems
• Negative Sentiment: Company had disclosed the incident to the SEC earlier in March; lingering uncertainty around remediation costs, potential supply/servicing disruption, and any customer impact keeps downside risk for the stock until full restoration and forensic results are confirmed. Stryker Addresses and Contains Recent Cybersecurity Incident

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on SYK shares. The Goldman Sachs Group set a $399.00 target price on Stryker in a research note on Friday, January 9th. BTIG Research increased their price target on Stryker from $410.00 to $412.00 and gave the company a “buy” rating in a research report on Friday, January 30th. Truist Financial cut their price objective on Stryker from $400.00 to $392.00 and set a “hold” rating on the stock in a research report on Thursday, December 18th. Jefferies Financial Group restated a “buy” rating and issued a $465.00 price objective on shares of Stryker in a research note on Wednesday, March 4th. Finally, Robert W. Baird set a $437.00 target price on Stryker in a research report on Friday, January 30th. Fourteen investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $427.50.

Stryker Stock Performance

NYSE:SYK opened at $332.48 on Tuesday. The business’s fifty day moving average is $362.68 and its 200 day moving average is $365.29. The firm has a market cap of $127.24 billion, a price-to-earnings ratio of 39.58, a PEG ratio of 1.96 and a beta of 0.85. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89. Stryker Corporation has a 52-week low of $328.23 and a 52-week high of $404.87.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, topping the consensus estimate of $4.40 by $0.07. The business had revenue of $7.17 billion during the quarter, compared to the consensus estimate of $7.12 billion. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The firm’s revenue was up 11.4% compared to the same quarter last year. During the same quarter last year, the company earned $4.01 EPS. Research analysts predict that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Tuesday, March 31st. Stryker’s dividend payout ratio (DPR) is 41.90%.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 250,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the completion of the transaction, the director owned 2,457,331 shares of the company’s stock, valued at approximately $891,814,566.52. The trade was a 9.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 5.20% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.